
## Christopher A Lipinski

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1127710/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	High throughput in vivo phenotypic screening for drug repurposing: Discovery of MLR-1023 a novel insulin sensitizer and novel Lyn kinase activator with clinical proof of concept. Bioorganic and Medicinal Chemistry, 2020, 28, 115425.	1.4	10
2	The rule of five should not impede anti-parasitic drug development. International Journal for Parasitology: Drugs and Drug Resistance, 2017, 7, 248-249.	1.4	36
3	Rule of five in 2015 and beyond: Target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions. Advanced Drug Delivery Reviews, 2016, 101, 34-41.	6.6	350
4	Badapple: promiscuity patterns from noisy evidence. Journal of Cheminformatics, 2016, 8, 29.	2.8	85
5	Thermodynamic Proxies to Compensate for Biases in Drug Discovery Methods. Pharmaceutical Research, 2016, 33, 194-205.	1.7	20
6	Parallel Worlds of Public and Commercial Bioactive Chemistry Data. Journal of Medicinal Chemistry, 2015, 58, 2068-2076.	2.9	28
7	Small molecules with antiviral activity against the Ebola virus. F1000Research, 2015, 4, 38.	0.8	33
8	Computational Prediction and Validation of an Expert's Evaluation of Chemical Probes. Journal of Chemical Information and Modeling, 2014, 54, 2996-3004.	2.5	22
9	ADMET Screen. , 2014, , 1-5.		0
10	ADMET Screen. , 2014, , 106-111.		0
11	My Perspective on Time, Managers—and Scientific Fun. Annual Reports in Medicinal Chemistry, 2013, 48, 15-22.	0.5	2
12	MLR-1023 Is a Potent and Selective Allosteric Activator of Lyn Kinase In Vitro That Improves Glucose Tolerance In Vivo. Journal of Pharmacology and Experimental Therapeutics, 2012, 342, 15-22.	1.3	33
13	The Lyn Kinase Activator MLR-1023 Is a Novel Insulin Receptor Potentiator that Elicits a Rapid-Onset and Durable Improvement in Glucose Homeostasis in Animal Models of Type 2 Diabetes. Journal of Pharmacology and Experimental Therapeutics, 2012, 342, 23-32.	1.3	35
14	Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 2012, 64, 4-17.	6.6	1,407
15	Phenotypic and <i>In Vivo</i> Screening: Lead Discovery and Drug Repurposing. RSC Drug Discovery Series, 2012, , 86-93.	0.2	4
16	ADMET Screen. , 2011, , 80-84.		0
17	Analysis and hit filtering of a very large library of compounds screened against Mycobacterium tuberculosis. Molecular BioSystems, 2010, 6, 2316-2324.	2.9	69
18	A crowdsourcing evaluation of the NIH chemical probes. Nature Chemical Biology, 2009, 5, 441-447.	3.9	111

#	Article	IF	CITATIONS
19	Overview of Hit to Lead: The Medicinal Chemist's Role from HTS Retest to Lead Optimization Hand Off. Topics in Medicinal Chemistry, 2009, , 1-24.	0.4	5
20	Synthesis and antitubercular activity of 7-(R)- and 7-(S)-methyl-2-nitro-6-(S)-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazines, analogues of PA-824. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2256-2262.	1.0	62
21	Compound Properties and Drug Quality. , 2008, , 481-490.		4
22	ADMET Screen. , 2008, , 74-77.		0
23	The anti-intellectual effects of intellectual property. Current Opinion in Chemical Biology, 2006, 10, 380-383.	2.8	9
24	High Throughput Sonication: Evaluation for Compound Solubilization. Combinatorial Chemistry and High Throughput Screening, 2005, 8, 499-512.	0.6	52
25	Chemical Tools for Indications Discovery. Annual Reports in Medicinal Chemistry, 2005, 40, 339-348.	0.5	6
26	Capter 11 Filtering in Drug Discovery. Annual Reports in Computational Chemistry, 2005, 1, 155-168.	0.9	38
27	Navigating chemical space for biology and medicine. Nature, 2004, 432, 855-861.	13.7	919
28	Lead- and drug-like compounds: the rule-of-five revolution. Drug Discovery Today: Technologies, 2004, 1, 337-341.	4.0	3,723
29	COMPOUND PROPERTIES AND DRUG QUALITY. , 2003, , 341-349.		12
30	Single-Mode Compound Retrieval for QSAR, QSPR Data Sets, and Batch Mode Exact Structure Searching. Journal of Pharmaceutical Sciences, 2002, 91, 2470-2472.	1.6	3
31	Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1. Advanced Drug Delivery Reviews, 2001, 46, 3-26.	6.6	11,703
32	Drug-like properties and the causes of poor solubility and poor permeability. Journal of Pharmacological and Toxicological Methods, 2000, 44, 235-249.	0.3	2,921
33	Quantitative Structureâ^'Activity Relationships among Macrolide Antibacterial Agents:Â In Vitro and in Vivo Potency againstPasteurella multocida. Journal of Medicinal Chemistry, 1997, 40, 1340-1346.	2.9	144
34	Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 1997, 23, 3-25.	6.6	8,880
35	Hydantoin bioisosteres. In vivo active spiro hydroxy acetic acid aldose reductase inhibitors. Journal of Medicinal Chemistry, 1992, 35, 2169-2177.	2.9	39
36	pKa, Log P and MedChem CLOGP Fragment Values of Acidic Heterocyclic Potential Bioisosteres. QSAR and Combinatorial Science, 1991, 10, 109-117.	1.4	28

#	Article	IF	CITATIONS
37	Physical parameters for brian uptake: optimizing log P, log D and pKa of T H A. Bioorganic and Medicinal Chemistry Letters, 1991, 1, 411-414.	1.0	24
38	<i>N</i> hlorination of dilantin and sorbinil. Journal of Heterocyclic Chemistry, 1990, 27, 1793-1799.	1.4	9
39	Acidic isostere design: Synthetic strategies and recent progress in understanding electronic properties and metabolic stability. Pest Management Science, 1990, 29, 227-240.	0.7	8
40	Medicinal chemistry of aldose reductase inhibitors. Medicinal Research Reviews, 1988, 8, 159-186.	5.0	43
41	Chapter 27. Bioisosterism in Drug Design. Annual Reports in Medicinal Chemistry, 1986, 21, 283-291.	0.5	86
42	Bioisosteric prototype design of biaryl imidazolyl and triazolyl competitive histamine H2-receptor antagonists. Journal of Medicinal Chemistry, 1986, 29, 2154-2163.	2.9	31
43	Pseudosymmetry and bioisosterism in biaryl pyridyl competitive histamine H2-receptor antagonists. Journal of Medicinal Chemistry, 1985, 28, 1628-1636.	2.9	21
44	2â€Amino―and 2â€guanidinoâ€4â€ŧhiazolylpyrimidines. Journal of Heterocyclic Chemistry, 1985, 22, 1723-17	261.4	9
45	Chapter 17. Aldose Reductase Inhibitors as a New Approach to the Treatment of Diabetic Complications. Annual Reports in Medicinal Chemistry, 1984, 19, 169-177.	0.5	27
46	An improved preparation and use of 2-bromoacetoacetaldehyde in a new synthesis of 2-substituted-4-acetylimidazoles. Journal of Organic Chemistry, 1984, 49, 566-570.	1.7	17
47	Bioisosteric design of conformationally restricted pyridyltriazole histamine H2-receptor antagonists. Journal of Medicinal Chemistry, 1983, 26, 1-6.	2.9	34
48	Chapter 10. Agents Affecting Gastrointestinal Functions. Annual Reports in Medicinal Chemistry, 1977, 12, 91-100.	0.5	0
49	Chapter 10. Agents Affecting Gastrointestinal Functions. Annual Reports in Medicinal Chemistry, 1975, , 90-98.	0.5	0
50	Total synthesis of terpenes. XIX. Synthesis of 8-methoxy-4a.beta., 10b.beta., 12a.alphatrimethyl-3,4,4a,4b.alpha.,5,6,10b,11,12,12a-decahydrochrysen-1(2H)-one, a key intermediate in the total synthesis of (+-)-shionone. Journal of Organic Chemistry, 1975, 40, 973-990.	1.7	21
51	Total synthesis of dl-shionone, a tetracyclic triterpene. Journal of the American Chemical Society, 1974, 96, 3333-3335.	6.6	24
52	Transmission of substituent effects in heterocycles. Rates of solvolysis of substituted 1-(2-thienyl)ethyl p-nitrobenzoates. Journal of Organic Chemistry, 1972, 37, 2615-2620.	1.7	22
53	The utility of the coupling reaction between propargyl grignard reagent and allylic halides for the synthesis of acetylenes. Tetrahedron Letters, 1970, 11, 2247-2250.	0.7	20
54	Correlation of the reactivity of thiophene derivatives. Journal of Organic Chemistry, 1970, 35, 1718-1720.	1.7	12